Orgenesis ( (ORGS) ) has released its Q3 earnings. Here is a breakdown of the information Orgenesis presented to its investors.
Orgenesis Inc. is a global biotechnology company that focuses on unlocking the potential of cell and gene therapies through an accessible format, primarily working on autologous therapies. The company operates in two segments: Octomera, which manages point-of-care services, and Therapies, which handles therapy-related activities. In their latest earnings report for the period ending September 30, 2024, Orgenesis has shown significant losses amidst a challenging financial environment.
The latest earnings report highlights a net loss of $28.6 million for the nine months ending September 30, 2024, which is a decrease compared to the $58.3 million loss in the same period in 2023. The company reported revenues of $734,000, up from $365,000 in the prior year. However, this was offset by a gross loss of $881,000, increased operating expenses, and a significant operating loss of $21.6 million. The deconsolidation of certain subsidiaries and challenges related to a Nasdaq delisting have also impacted the company’s performance.
Key financial metrics include a reduction in cash and cash equivalents to $204,000 from $837,000 at the end of 2023, and a substantial accumulated deficit of over $204 million. The company’s liabilities have increased, with current liabilities rising to $36 million from $16.4 million at the end of the previous year. Orgenesis also reported impairment expenses and financial expenses impacting their overall financial health.
Despite the financial struggles, Orgenesis is actively pursuing strategies to mitigate their challenges. The company is focusing on raising additional capital, exploring strategic acquisitions, and improving revenue streams to address liquidity issues and support operational needs. The management remains cautious but optimistic about the potential for future growth through strategic initiatives and cost management efforts.
